Skip to main navigation Skip to search Skip to main content

Recurrent Intrahepatic Cholangiocarcinoma: A 10-Point Score to Predict Post-Recurrence Survival and Guide Treatment of Recurrence

  • Diamantis I Tsilimigras
  • , Yutaka Endo
  • , Alfredo Guglielmi
  • , Luca Aldrighetti
  • , Matthew Weiss
  • , Todd W Bauer
  • , Irinel Popescu
  • , George A Poultsides
  • , Shishir K Maithel
  • , Hugo P Marques
  • , Guillaume Martel
  • , Carlo Pulitano
  • , Feng Shen
  • , François Cauchy
  • , Bas Groot Koerkamp
  • , Itaru Endo
  • , Timothy M Pawlik*
  • *Corresponding author for this work
  • The James Comprehensive Cancer Center
  • University of Verona
  • Department of Surgery
  • Johns Hopkins Hospital
  • University of Virginia
  • Fundeni Clinical Institute
  • Stanford University
  • Emory University
  • Hospital Curry Cabral
  • University of Ottawa
  • The University of Sydney
  • Eastern Hepatobiliary Surgery Hospital
  • Beaujon Hospital
  • Yokohama City University Graduate School of Medicine

Research output: Contribution to journalArticleAcademicpeer-review

15 Citations (Scopus)
16 Downloads (Pure)

Abstract

INTRODUCTION: 

Although up to 50-70% of patients with intrahepatic cholangiocarcinoma (ICC) recur following resection, data to predict post-recurrence survival (PRS) and guide treatment of recurrence are limited.

METHODS: 

Patients who underwent resection of ICC between 2000 and 2020 were identified from an international, multi-institutional database. Data on primary disease as well as laboratory and radiologic data on recurrent disease were collected. Factors associated with PRS were examined and a novel scoring system to predict PRS (PRS score) was developed and internally validated.

RESULTS: 

Among 986 individuals who underwent resection for ICC, 588 (59.6%) patients developed recurrence at a median follow up of 20.3 months. Among patients who experienced a recurrence, 97 (16.5%) underwent re-resection/ablation for recurrent ICC; 88 (15.0%) and 403 (68.5%) patients received intra-arterial treatment or systemic chemotherapy/supportive therapy, respectively. Patient American Society of Anesthesiologists (ASA) class > 2 (1 point), primary tumor N1/Nx status (1 point), primary R1 resection margin (1 point), primary tumor G3/G4 grade (1 point), carbohydrate antigen (CA) 19-9 > 37 UI/mL (2 points) at recurrence and carcinoembryonic antigen (CEA) > 5 ng/mL (2 points) at recurrence, as well as recurrent bilateral disease (1 point) and early recurrence (1 point) were included in the PRS score. The PRS score successfully stratified patients relative to PRS and demonstrated strong discriminatory ability (C-index 0.70, 95% confidence interval 0.68-0.72). While a PRS score of 0-3 was associated with a 3-year PRS of 62.5% following resection/ablation for recurrent ICC, a PRS score > 3 was associated with a low 3-year PRS of 35.5% (p = 0.03).

CONCLUSIONS: 

The PRS score demonstrated strong discriminatory ability to predict PRS among patients who had developed recurrence following initial resection of ICC. The PRS score may be a useful tool to guide treatment among patients with recurrent ICC.

Original languageEnglish
Pages (from-to)4427-4435
Number of pages9
JournalAnnals of Surgical Oncology
Volume31
Issue number7
DOIs
Publication statusPublished - Jul 2024

Bibliographical note

Publisher Copyright:
© Society of Surgical Oncology 2024.

Fingerprint

Dive into the research topics of 'Recurrent Intrahepatic Cholangiocarcinoma: A 10-Point Score to Predict Post-Recurrence Survival and Guide Treatment of Recurrence'. Together they form a unique fingerprint.

Cite this